Cabozantinib Capsule
Generic name: Cabozandr
Product name: Cabozantinib Capsule
Preparation: Capsule
Specification: 20mg/30
Product
Cabozantinib, sold under the brand name Cabozandr among others, is a medication used to treat medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET
In November 2012, cabozantinib in its capsule formulation was approved by the U.S. Food and Drug Administration (FDA) under the name Cometriq for treating patients with medullary thyroid cancer.The capsule form was approved in the European Union for the same purpose in 2014
In April 2016, the FDA granted approval for marketing the tablet formulation as a second line treatment for kidney cancer[10][11] and the same was approved in the European Union in September of that year.
